your badges 52W Range $15–$34 20% of range Analyst Rating STRONG BUY 15 analysts Price Target $35 +91% upside P/E · ROE · Net Profit Margin ·

AKTS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $18.52
Market Cap (MRQ) $990M
52W Range $15–$34

AKTS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

10-Year Performance Revenue, net income, margins and EPS trends

06
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend AKTS 5Y avg Peer Median Verdict
P/B (MRQ) 2.0 · · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 19.4%
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 13, 2026 $-0.44 $-0.43 -1.3%
March 31, 2026 $-0.38 $-0.34 -11.5%
Dec. 31, 2025 $-0.30 $-1.04 71.2%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Balance Sheet 18
Metric Trend 2025
Cash & Equivalents $38M
Prepaid Expense $4M
Current Assets $230M
PP&E (Net) $15M
PP&E (Gross) $20M
Accum. Depreciation $6M
Total Assets $265M
Accounts Payable $2M
Accrued Liabilities $10M
Current Liabilities $31M
Capital Leases $10M
Total Liabilities $78M
Common Stock $0
Retained Earnings $-157M
AOCI $42.0K
Stockholders' Equity $-146M
Liabilities + Equity $265M
Shares Outstanding 915,261

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
No data for this statement

Not enough fundamentals data to build this statement yet.

Institutional owners (13F) 114 filers · $992.4M total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 114
Value held $992.4M
New positions 52
Exited positions 6
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
52 6 27 16 ·

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.

Institution Value Shares % of tracked 13F Type
MPM BIOIMPACT LLC $155,860,155 4,835,872 15.71% Shares
EcoR1 Capital, LLC $155,492,636 4,824,469 15.67% Shares
Blue Owl Capital Holdings LP $98,953,158 3,070,219 9.97% Shares
BlackRock, Inc. $73,431,479 2,278,358 7.40% Shares
WELLINGTON MANAGEMENT GROUP LLP $63,372,044 1,966,244 6.39% Shares
RTW INVESTMENTS, LP $51,311,546 1,592,043 5.17% Shares
RA CAPITAL MANAGEMENT, L.P. $42,363,273 1,314,405 4.27% Shares
BAKER BROS. ADVISORS LP $32,112,393 996,351 3.24% Shares
Octagon Capital Advisors LP $30,968,099 960,847 3.12% Shares
Merck & Co., Inc. $30,710,162 952,844 3.09% Shares
VANGUARD CAPITAL MANAGEMENT LLC $26,334,327 817,075 2.65% Shares
JANUS HENDERSON GROUP PLC $26,022,437 1,454,267 2.62% Shares
TCG Crossover Management, LLC $22,450,129 696,560 2.26% Shares
GEODE CAPITAL MANAGEMENT, LLC $16,787,478 520,737 1.69% Shares
EVENTIDE ASSET MANAGEMENT, LLC $16,340,610 507,000 1.65% Shares
Avidity Partners Management LP $15,605,766 484,200 1.57% Shares
STATE STREET CORP $15,599,642 484,010 1.57% Shares
a16z Capital Management, L.L.C. $13,375,450 415,000 1.35% Shares
Alyeska Investment Group, L.P. $9,346,700 290,000 0.94% Shares
FMR LLC $9,205,887 285,631 0.93% Shares
ArrowMark Colorado Holdings LLC $7,924,455 245,872 0.80% Shares
NORTHERN TRUST CORP $5,819,933 180,575 0.59% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $5,377,318 166,842 0.54% Shares
BARCLAYS PLC $4,889,163 151,696 0.49% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $4,680,441 145,220 0.47% Shares
VANGUARD FIDUCIARY TRUST CO $4,313,470 133,834 0.43% Shares
TD Asset Management Inc $3,413,221 105,902 0.34% Shares
SOROS FUND MANAGEMENT LLC $3,223,000 100,000 0.32% Shares
Woodline Partners LP $3,223,000 100,000 0.32% Shares
UBS Group AG $3,221,711 99,960 0.32% Shares
RENAISSANCE TECHNOLOGIES LLC $3,074,742 95,400 0.31% Shares
BANK OF AMERICA CORP /DE/ $2,347,472 72,835 0.24% Shares
POLEN CAPITAL MANAGEMENT LLC $2,047,056 63,514 0.21% Shares
MORGAN STANLEY $2,018,758 62,636 0.20% Shares
RAYMOND JAMES FINANCIAL INC $1,626,455 50,464 0.16% Shares
Nuveen, LLC $1,605,569 49,816 0.16% Shares
Bank of New York Mellon Corp $1,587,324 49,250 0.16% Shares
AQR CAPITAL MANAGEMENT LLC $1,551,005 48,123 0.16% Shares
MANUFACTURERS LIFE INSURANCE COMPANY, THE $1,548,458 48,044 0.16% Shares
Quantinno Capital Management LP $1,511,168 46,887 0.15% Shares
GREAT LAKES ADVISORS, LLC $1,405,615 43,612 0.14% Shares
Mirador Capital Partners LP $1,293,197 40,124 0.13% Shares
Squarepoint Ops LLC $1,237,020 38,381 0.12% Shares
Jump Financial, LLC $1,056,467 32,779 0.11% Shares
Sofinnova Investments, Inc. $1,045,412 32,436 0.11% Shares
TWO SIGMA INVESTMENTS, LP $996,358 30,914 0.10% Shares
READYSTATE ASSET MANAGEMENT LP $966,900 30,000 0.10% Shares
WELLS FARGO & COMPANY/MN $891,450 27,659 0.09% Shares
RHUMBLINE ADVISERS $868,429 26,945 0.09% Shares
CITADEL ADVISORS LLC $823,058 25,537 0.08% Shares

Show all 114 institutional owners →

Activists & 5%+ owners 4 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
MPM BIOVENTURES 2018, L.P., MPM BIOVENTURES 2018 (B), L.P., MPM BioVentures 2018 GP LLC, MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, MPM BioVentures 2018 LLC, MPM ONCOLOGY INNOVATIONS FUND LP, MPM Oncology Innovations Fund GP LLC, Oncology Impact Private Investment Fund 2, L.P., MPM Oncology Investments 2 LLC, MPM ASSET MANAGEMENT LLC, ANSBERT GADICKE, LUKE EVNIN, Todd Foley Jan. 20, 2026 19.30% Initial filing Passive investment SEC
EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. Jan. 20, 2026 9.10% Initial filing Passive investment SEC
Eli Lilly and Company Jan. 15, 2026 11.90% Initial filing Passive investment SEC
Vida Ventures II, LLC, Vida Ventures II-A, LLC, VV Manager II LLC, Helen Kim Jan. 14, 2026 10.90% Initial filing Passive investment SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 7 insiders · 2 officers · 5 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Shulamit Ron-Bigger Chief Operating Officer July 8, 2026 M 0 0 3 $-1,387,604
Akos Czibere Chief Medical Officer Sept. 23, 2026 M 0 0 5 $-1,647,278
Ken Herrmann Director July 20, 2026 M 0 0 3 $-196,532
Glenn Gormley Director April 15, 2026 A · 0 0 $0
Lloyd Mitchell Segal Director Jan. 12, 2026 C 19,631 0 0 $0
Todd Foley Director Jan. 12, 2026 C 4,235,403 1 0 $4,191,660
Helen Kim Director Jan. 12, 2026 C 157,387 2 0 $15,030,000

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 15 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
BBC · ETFis Series Trust I 0.67% 14,173 NS July 31, 2026 N-PORT
VTWG · VANGUARD SCOTTSDALE FUNDS 0.03% 15,659 SH Aug. 19, 2026 Daily
IWO · iShares Trust 0.02% 137,170 SH Sept. 11, 2026 Daily
OMFS · Invesco Exchange-Traded Self-Indexe… 0.02% 3,261 SH Oct. 2, 2026 Daily
VTWO · VANGUARD SCOTTSDALE FUNDS 0.02% 122,067 SH Aug. 19, 2026 Daily
IWM · iShares Trust 0.02% 540,793 SH Sept. 11, 2026 Daily
RSSL · Global X Funds 0.02% 10,145 NS July 31, 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0.01% 213,673 SH Aug. 19, 2026 Daily
VTWV · VANGUARD SCOTTSDALE FUNDS 0.01% 5,760 SH Aug. 19, 2026 Daily
IWV · iShares Trust 0.00% 9,577 SH Sept. 10, 2026 Daily
ITOT · iShares Trust 0.00% 34,283 SH Sept. 11, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.00% 585,135 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.00% 1,734 SH Aug. 19, 2026 Daily
IWN · iShares Trust · 59,457 SH Sept. 11, 2026 Daily
ISCB · iShares Trust · 904 SH Sept. 11, 2026 Daily

AKTS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 15 analysts BUY
Median target $35.00 +89.0%
7 46.7% Strong Buy
7 46.7% Buy
1 6.7% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

9 analysts · 2026-09-28

Mean target $35.39 +91.1%

← Below all targets Current price $18.52
Low$31.50 Mean$35.39 High$40.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
AKTS · · · · · ·
BCAX $953M -6.7 · · -33.0% ·
VOR $506M -0.2 · · 83.4% ·
JANX $833M -7.5 -5.5% -1136.2% -11.7% ·
SVRA $1.23B -11.4 · · -73.4% ·
MGTX $645M -5.6 144.6% -140.3% 8062.2% ·
ODTX · · · · · ·
KURA $913M -3.3 25.2% -413.0% -116.2% ·
CGEM $624M -3.2 · · -44.0% ·

Latest News Recent headlines mentioning this company

23
H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33 Yahoo Finance · 5 months, 3 weeks ago

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 13, 2026